Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
An initial belantamab mafodotin dose of 2.5 mg/kg for BVd yields deeper responses with minimal change in safety outcomes versus 1.9 mg/kg for patients with RRMM.
Axillary surgery remains the main predictor of long-term arm lymphoedema following locoregional radiotherapy for node-positive breast cancer, supporting de-escalation of.
In patients undergoing CRS for PMP, these results provide supportive evidence for the hemostatic efficacy of FC, consistent with the overall trial and prior studies, with a favorable safety profile.
No covariates were associated with ORR.
Baseline 18F-FDG PET-derived metabolic and radiomic parameters do not provide meaningful incremental prognostic value beyond tumour burden and clinical factors.
Berotralstat significantly improved HRQoL versus placebo through 24 weeks and showed long-term beneficial effects through 96 weeks.
Three external reference anchors were used to assess known-groups validity, based on clinician and study partner ratings of disease severity over time.
Selective omission of dexamethasone after the second weekly paclitaxel infusion was safe and well tolerated in this randomized trial.
In NPC patients achieving CR/PR after induction chemotherapy, IC + RT demonstrated a favorable safety profile compared with IC+CCRT.
This is first application of an integrated item-level IRT-BI-FREM approach in CD, enabling robust characterization of placebo response and identification of clinically relevant covariates.
Obicetrapib lowered LDL-C, apoB and Lp(a).
37%, 41%, and 44%, respectively; P<0.001, P=0.004, and P=0.002) and QOL across different measures of response (43-53% vs.
Individualized NIs significantly improve QoL and nutritional status in patients with NPC undergoing radiation therapy, underscoring the importance of ongoing assessment-guided individualized nutritional support.
The preHD-ET for 36 weeks improves systemic aerobic capacity in ESRD patients.
Baseline tCFS score and ametropia are critical factors associated with SHR8058 treatment response.
Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD.
The mean CFB in MADRS demonstrated separation between esmethadone and placebo arms for patients with a baseline score of 35 or higher.
Repeated onabotA treatment is well tolerated and improves platysma prominence over the course of multiple treatment cycles.
Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, death within 90 days and mRS 5-6 at 90 days.
Nipocalimab + SOC demonstrated early and sustained fatigue and HRQoL improvements over 24 weeks.
Baseline serum proteomics captures core disease characteristics of MG and predicts short-term clinical response in a treatment-specific manner.
XXL was a compared against a dummy pill (placebo) phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit).
These phase III trials demonstrate that KJ017 effectively enhances gravity-driven SC infusion performance while maintaining favorable safety and tolerability.
Early and sustained efficacy with depemokimab was observed across 26-week dosing periods in type 2 asthma, with enhanced benefits in patients with shorter disease duration who had not progressed to high-dose ICS.
Gene expression had limited prognostic value, and relapse DEGs differed by treatment.
CanTreatCOVID demonstrates feasibility of decentralized APTs in community settings.
Our findings support the efficacy of adjuvanted RSVPreF3 across a broad set of RSV strains, representative of globally circulating strains.
Time to surgery following neoadjuvant therapy did not significantly influence prognosis in advanced ESCC.
Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence.
In PCS-5, HFRT is a standard treatment for high-risk PCa receiving external beam RT.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
